Potent, orally active dipeptidyl peptidase (DPP)-IV inhibitor

Novel peptide deformylase (PDF) inhibitor; Antibacterial

Novel Syk inhibitor

Novel nonpeptide bradykinin B1 receptor antagonist

The first non-peptide somatostatin sst(1) receptor antagonist

Novel focal adhesion kinase (FAK) inhibitor, potently blocking kinase activity of FAK along with Aurora A, activated Cdc42-associated kinase 1 (ACK1), Met, insulin receptor (IR), TrkA, and IGF-1R

Specific inhibitor of the 25-hydroxyvitamin D(3)-24-hydroxylase (24-hydroxylase)

Novel potent PKCθ inhibitor

Novel selective bromodomain and extra-terminal domain (BET) protein family inhibitor (BETi ), inducing an ‘activated’ keratinocyte transcriptional profile with reversal of chronic wound biomarkers in human skin ex vivo

Novel Potent and Selective inhibitor of YEATS proteins

Negative control for NVS-PAK1-1 (8778)

Potent, orally active, small-molecule enhancer of SMN2 splicing, binding to and stabilizing the U1 snRNP:5′ss RNA complex

Exceptional oxygen transporter, increasing brain tissue oxygen tension (PbtO2) when administered soon after traumatic brain injury (TBI)

Highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor

Novel potent Hsp90 inhibitor, inducing tumor regression in a genetically engineered mouse model of glioblastoma multiforme

Selective nNOS inhibitor and a5-HT1B/1D receptor agonist

Anti-microbial agent against Mycobacterium smegmatis and Mycobacterium bovis BCG, binding to DNA and inducing a unique morphological change to mycobacterial bacilli leading the bacterial cell death

Cancer-testis antigen (CTA) with re-expression in numerous cancer types, eliciting spontaneous humoral and cellular immune responses, restricting expression pattern, being a good candidate target for cancer immunotherapy

Novel water-soluble nystatin derivative, being fully water-soluble (up to 1 g/mL) with the same potency of Nystatin but with 13.5 times lower toxicity

Potent CB1 receptor antagonist

Novel inhibitor of advanced stages of breast cancer, targeting multiple cannabinoid anti-tumour pathways

Novel GPR18 antagonist, blocking the effects of Abn-CBD and NAGly.